Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 31.91

+1.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Douglas who wrote (239)	8/25/1997 9:22:00 PM
From: Douglas	of 455

Subject: A Biotech Bash-Recs and Wrecks To: r. peter Dale (1 ) From: polar bear Aug 24 1997 12:28PM EST Reply #2 of 14 I agree with your pick of ARIAD. I like their technology, especially what they have going in the Gene Therapeutics group. Another sleeper that has had lots of trouble but has restructured is Procept (PRCT). They are in early stage clinical trials with a topical microbicide. If this product hits, their stock will take off. To: polar bear (2 ) From: r. peter Dale Aug 24 1997 1:18PM EST Reply #3 of 14 PB: Your choice certainly fits the mold. I'll look into Procept. I'd also be interested in hearing about such companies as Ligand, IDEC, Cytogen, Anergen, etc. in a forum where their strengths and weaknesses can be compared. Best wishes, Peter Note - of course there were typos in post #1: in the Ariad blurb 'personal' should be 'personnel' and 'Zachs' should be 'Zack's'. To: polar bear (2 ) From: r. peter Dale Aug 24 1997 4:34PM EST Reply #4 of 14 PB: The SEC statement of Procept appears to be consistent with many other development stage companies: from all outward appearences its horrific. But if they are able to survive these financial difficulties, some companies prosper. I did not read the entire SEC document (very long!) nor am I familiar with Procept's products. What are the unique features of their tropical microbicide? Procept's stock performance may serve as an example of the entire biotech field at the moment. The example I'm most familiar with is Univec - a company with real products and actual sales and a stock price chart only a blind mother could 'associate with' ('love' would be asking too much). There are many other such stories. So this appears to be time of little tolerence for risk in biotech and even less patience for R&D. In other words, a buying opportunity. Who could disagree? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next